[1]潘佳君,徐志云.主动脉瓣狭窄合并高血压的诊治进展[J].国际心血管病杂志,2024,03:133-136,152.
点击复制
主动脉瓣狭窄合并高血压的诊治进展(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2024年03期
- 页码:
- 133-136,152
- 栏目:
- 综述
- 出版日期:
- 2024-05-20
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2024.03.002
- 文献标识码:
- -
- 摘要:
- 主动脉瓣狭窄（AS）和高血压常合并存在。高血压可增加AS 发生、进展的 风险，且可加重患者左室负荷，影响心脏功能。合并高血压的AS 患者临床症状出现较早，不 良预后风险增加，行超声心动图检查可能会低估AS 的严重程度。血管紧张素转换酶抑制 剂或血管紧张素受体阻滞剂可能是AS 合并高血压的首选降压药物，建议血压控制目标为 130~139/80~90 mmHg。对于严重AS 患者，应积极外科手术或介入治疗。
- Abstract:
- -
参考文献/References
[1] Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and
stroke statistics-2021 update: a report from the American Heart
Association[J]. Circulation, 2021, 143(8):e254-e743.
[2] Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS
guidelines for the management of valvular heart disease[J]. Eur
Heart J, 2022, 43(7):561-632.
[3] Iung B, Delgado V, Rosenhek R, et al. Contemporary
presentation and management of valvular heart disease: the
EURObservational research programme valvular heart disease Ⅱ
survey[J]. Circulation, 2019, 140(14):1156-1169.
[4] Eveborn GW, Schirmer H, Heggelund G, et al. The evolving
epidemiology of valvular aortic stenosis. the Troms? study[J].
Heart, 2013, 99(6):396-400.
[5] Mancia G, Kreutz R, Brunstr?m M, et al. 2023 ESH guidelines
for the management of arterial hypertension the task force
for the management of arterial hypertension of the European
society of hypertension: endorsed by the International Society of
Hypertension (ISH) and the European Renal Association (ERA)
[J]. J Hypertens, 2023, 41(12):1874-2071.
[6] Rahimi K, Mohseni H, Kiran A, et al. Elevated blood pressure
and risk of aortic valve disease: a cohort analysis of 5.4 million
UK adults[J]. Eur Heart J, 2018, 39(39):3596-3603.
[7] Yan AT, Koh M, Chan KK, et al. Association between cardiovascular
risk factors and aortic stenosis: the CANHEART aortic stenosis
study[J]. J Am Coll Cardiol, 2017, 69(12):1523-1532.
[8] Basile C, Fucile I, Lembo M, et al. Arterial hypertension in
aortic valve stenosis: a critical update[J]. J Clin Med, 2021,
10(23):5553.
[9] Bahlmann E, Cramariuc D, Saeed S, et al. Low systemic
arterial compliance is associated with increased cardiovascular
morbidity and mortality in aortic valve stenosis[J]. Heart, 2019,
105(19):1507-1514.
[10] Rieck AE, Cramariuc D, Staal EM, et al. Impact of hypertension
on left ventricular structure in patients with asymptomatic
aortic valve stenosis (a SEAS substudy)[J]. J Hypertens, 2010,
28(2):377-383.
[11] Cramariuc D, Rogge BP, L?nnebakken MT, et al. Sex differences
in cardiovascular outcome during progression of aortic valve
stenosis[J]. Heart, 2015, 101(3):209-214.
[12] Tadic M, Cuspidi C, Pencic B, et al. The impact of arterial
hypertension on left ventricular strain in patients with aortic
stenosis and preserved ejection fraction[J]. J Hypertens, 2019,
37(4):747-753.
[13] Mancusi C, de Simone G, Brguljan Hitij J, et al. Management
of patients with combined arterial hypertension and aortic
valve stenosis: a consensus document from the Council on
Hypertension and Council on Valvular Heart Disease of the
European Society of Cardiology, the European Association of
Cardiovascular Imaging (EACVI), and the European Association
of Percutaneous Cardiovascular Interventions (EAPCI)[J]. Eur
Heart J Cardiovasc Pharmacother, 2021, 7(3):242-250.
[14] Kadem L, Dumesnil JG, Rieu R, et al. Impact of systemic
hypertension on the assessment of aortic stenosis[J]. Heart, 2005,
91(3):354-361.
[15] Saeed S, Mancia G, Rajani R, et al. Hypertension in aortic stenosis:
relationship with revealed symptoms and functional measures on
treadmill exercise[J]. J Hypertens, 2019, 37(11):2209-2215.
[16] Nielsen OW, Sajadieh A, Sabbah M, et al. Assessing optimal
blood pressure in patients with asymptomatic aortic valve
stenosis: the simvastatin ezetimibe in aortic stenosis study
(SEAS)[J]. Circulation, 2016, 134(6):455-468.
[17] Rassa A, Zahr F. Hypertension and aortic stenosis: a review[J].
Curr Hypertens Rev, 2018, 14(1):6-14.
[18] Hachicha Z, Dumesnil JG, Pibarot P. Usefulness of the
valvuloarterial impedance to predict adverse outcome in
asymptomatic aortic stenosis[J]. J Am Coll Cardiol, 2009,
54(11):1003-1011.
[19] Lindman BR, Otto CM, Douglas PS, et al. Blood pressure and
arterial load after transcatheter aortic valve replacement for aortic
stenosis[J]. Circ Cardiovasc Imaging, 2017, 10(7):e006308.
[20] Klinkhammer BJ, Dyke CM, Haldis TA. The development
or worsening of hypertension after transcatheter aortic valve
replacement (TAVR) improves short-term and long-term patient
outcomes[J]. Heart Asia, 2018, 10(2):e010994.
[21] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA
guideline for the management of patients with valvular heart
disease: a report of the American College of Cardiology/
American Heart Association joint committee on clinical practice
guidelines[J]. J Am Coll Cardiol, 2021, 77(4):e25-e197.
[22] B?hm M, Schumacher H, Teo KK, et al. Achieved diastolic blood
pressure and pulse pressure at target systolic blood pressure (120-
140 mmHg) and cardiovascular outcomes in high-risk patients:
results from ONTARGET and TRANSCEND trials[J]. Eur Heart
J, 2018, 39(33):3105-3114.
[23] Vidal-Petiot E, Ford I, Greenlaw N, et al. Cardiovascular event
rates and mortality according to achieved systolic and diastolic
blood pressure in patients with stable coronary artery disease:
an international cohort study[J]. Lancet, 2016, 388(10056):
2142-2152.
[24] Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/
AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/
PCNA guideline for the prevention, detection, evaluation,
and management of high blood pressure in adults: executive
summary: a report of the American College of Cardiology/
American Heart Association task force on clinical practice
guidelines[J]. Circulation, 2018, 138(17):e426-e483.
[25] 中国高血压防治指南修订委员会, 高血压联盟, 中华医学会心
血管病学分会中国医师协会高血压专业委员会, 等. 中国高
血压防治指南（2018年修订版）[J]. 中国心血管杂志, 2019,
24(1):24-56.
[26] Goel SS, Kleiman NS, Zoghbi WA, et al. Renin-angiotensin
system blockade in aortic stenosis: implications before and
after aortic valve replacement[J]. J Am Heart Assoc, 2020,
9(18):e016911.
[27] Sen J, Chung E, Neil C, et al. Antihypertensive therapies in
moderate or severe aortic stenosis: a systematic review and metaanalysis[
J]. BMJ Open, 2020, 10(10):e036960.
[28] Rodriguez-Gabella T, Catalá P, Mu?oz-García AJ, et al. Reninangiotensin
system inhibition following transcatheter aortic valve
replacement[J]. J Am Coll Cardiol, 2019, 74(5):631-641.
[29] Chen S, Redfors B, Nazif T, et al. Impact of renin-angiotensin
system inhibitors on clinical outcomes in patients with severe
aortic stenosis undergoing transcatheter aortic valve replacement:
an analysis of from the PARTNER 2 trial and registries[J]. Eur
Heart J, 2020, 41(8):943-954.
[30] Stewart RA, Kerr AJ, Cowan BR, et al. A randomized trial of
the aldosterone-receptor antagonist eplerenone in asymptomatic
moderate-severe aortic stenosis[J]. Am Heart J, 2008, 156(2):348-
355.
[31] Hansson NH, S?rensen J, Harms HJ, et al. Metoprolol reduces
hemodynamic and metabolic overload in asymptomatic aortic
valve stenosis patients: a randomized trial[J]. Circ Cardiovasc
Imaging, 2017, 10(10):e006557.
[32] Bang CN, Greve AM, Rosseb? AB, et al. Antihypertensive
treatment with β-blockade in patients with asymptomatic aortic
stenosis and association with cardiovascular events[J]. J Am
Heart Assoc, 2017, 6(12):e006709.
[33] Saeed S, Mancia G, Rajani R, et al. Antihypertensive treatment
with calcium channel blockers in patients with moderate or
severe aortic stenosis: relationship with all-cause mortality[J]. Int
J Cardiol, 2020, 298:122-125.
[34] Eleid MF, Nishimura RA, Sorajja P, et al. Systemic hypertension
in low-gradient severe aortic stenosis with preserved ejection
fraction[J]. Circulation, 2013, 128(12):1349-1353.
[35] Amat-Santos IJ, Sánchez-Luna JP, Abu-Assi E, et al. Rationale
and design of the Dapagliflozin after Transcatheter Aortic Valve
Implantation (DapaTAVI) randomized trial[J]. Eur J Heart Fail,
2022, 24(3):581-588.
备注/Memo
- 备注/Memo:
-
基金项目：国家自然科学基金（82070402，81870287）
通信作者：徐志云， E-mail：drxuzhiyun_ch@163.com
常用功能
统计/Statistics
- 摘要浏览/Viewed97
- 全文下载/Downloads91
- 评论/Comments
